Welcome to our dedicated page for POMDOCTOR news (Ticker: POM), a resource for investors and traders seeking the latest updates and insights on POMDOCTOR stock.
POMDOCTOR LIMITED (NASDAQ: POM) is described as a leading online medical services platform for chronic diseases in China, with operations centered on an Internet hospital and a pharmaceutical supply chain. Company news provides insight into how this chronic disease-focused platform is developing its business model and responding to changes in China’s healthcare landscape.
News releases from Pomdoctor have covered topics such as the pricing, closing, and over-allotment of its initial public offering of American Depositary Shares on the Nasdaq Global Market under the ticker POM. These announcements outline details of the offering structure and the company’s access to capital through ADS issuance.
Pomdoctor’s updates also include unaudited financial results for reporting periods, where the company discusses net revenues, gross profit, segment performance for its Internet hospital and pharmaceutical supply chain, and the contribution of online pharmacy sales. In these communications, Pomdoctor has described efforts to strengthen cooperation with pharmaceutical manufacturers, expand its partner-doctor pool, and balance expansion with operational discipline.
Investors and observers using this news page can review Pomdoctor’s official announcements about its capital markets activities, financial performance, and operational focus on chronic disease management and pharmaceutical services in China. For those tracking POM stock, the news feed offers a centralized view of company-issued information related to its Internet hospital business, pharmaceutical supply chain operations, and strategic direction.
POMDOCTOR LIMITED (NASDAQ: POM) received a Nasdaq Deficiency Letter dated Jan 29, 2026, reporting the ADS closing bid price was below the required $1.00 minimum for 33 consecutive business days. The letter currently does not affect listing or trading.
The company has a 180-calendar-day compliance period ending July 28, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days; Nasdaq may grant additional time at its discretion.
Pomdoctor (NASDAQ: POM) said it is strengthening strategic collaborations with multiple domestic pharmaceutical companies to accelerate growth of its internet hospital business and enhance profitability. The company reported it has entered into sales and purchase agreements with several listed drug makers to supply innovative and patented products to its platforms, with entitlement to purchase discounts, rebates, and sales incentives tied to agreed sales targets. The release cites a fast-growing market backdrop: online drug sales in China rose to RMB 71.8 billion (≈US$10.3 billion) in 2024 with a 39.4% CAGR since 2020, which Pomdoctor says supports expansion of its nationwide internet hospital operations.
Pomdoctor (NASDAQ: POM) reported unaudited results for the six months ended June 30, 2025. Net revenue rose 16.2% to RMB174.5 million (US$24.4 million), driven by an 83.2% increase in online-pharmacy/Internet-hospital sales. Gross profit grew 16.3% to RMB28.3 million (US$4.0 million) with a stable gross margin of 16.2%. The company recorded a net loss of RMB19.9 million (US$2.8 million) and cash and cash equivalents were RMB5.7 million as of June 30, 2025. Pomdoctor completed its October 2025 IPO, raising gross proceeds of US$23,000,016.
POMDOCTOR (Nasdaq: POM) announced the underwriter fully exercised its over-allotment option to purchase 750,000 ADSs at $4.00 per ADS, with the over-allotment closing on October 10, 2025. Gross proceeds to the company from the Offering, including the prior closing and this exercise, totaled $23,000,016 before underwriting discounts and expenses. The ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker POM. The Offering was conducted on a firm commitment basis, with Joseph Stone Capital acting as underwriter. The SEC declared the company’s Form F-1 effective on September 30, 2025.
POMDOCTOR (Nasdaq: POM) closed its initial public offering on Oct 9, 2025, selling 5,000,004 ADSs at $4.00 per ADS (six ADSs equal one Class A ordinary share). The ADSs began trading on the Nasdaq Global Market on Oct 8, 2025 under ticker POM. The company received aggregate gross proceeds of approximately $20.0 million before underwriting discounts and expenses. The underwriter, Joseph Stone Capital, was granted a 45-day option to buy up to an additional 750,000 ADSs at the public offering price less underwriting discounts. The offering was conducted on a firm commitment basis.
POMDOCTOR (NASDAQ:POM) priced its initial public offering of 5,000,004 ADSs at $4.00 per ADS, implying aggregate gross proceeds of approximately $20.0 million before underwriting discounts and expenses. Six ADSs represent one Class A ordinary share. The ADSs were approved to list on the Nasdaq Global Market and are expected to commence trading on October 8, 2025 under the ticker POM. The offering is expected to close on or about October 9, 2025 and includes a 45-day underwriter option for 750,000 ADSs.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of POMDOCTOR (POM)?
What is the market cap of POMDOCTOR (POM)?
